ClinicaliQ Trial Snapshot
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) — Recruiting • Phase III • Respiratory / COPD / Asthma • NCT06881784.
- What is being tested: Daraxonrasib (RMC-6236), a novel RAS(ON) inhibitor, is being evaluated against docetaxel chemotherapy for safety and efficacy in patients with RAS-mutated non-small cell lung cancer (NSCLC).
- Patient eligibility overview: The trial enrolls patients with confirmed RAS mutations in advanced NSCLC who are appropriate candidates for treatment with either the investigational drug or standard chemotherapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Eligibility Snapshot
- : * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy. * Measurable disease per RECIST v1.1. * Adequate organ function (bone marrow, liver, kidney, coagulation). * One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy. * Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61). * Able to take oral medications.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.